Insights.

Essays on biotech business development, San Diego operator playbooks, and mid-cap biopharma operations. Written for CEOs, boards, and operators making the next decision, not the last one.

Capital markets

A crossover round with a ticker

Legacy shareholders in these deals keep about 1.8%. The split is not a verdict on the science, it is a formula keyed to the bank balance, and it says who the structure is really for.

8 min read

Capital markets

The window was never the point

The IPO window was supposed to be the thing that ended the reverse-merger wave. It reopened at record scale in 2026 and the structure thickened instead. The two were never substitutes.

8 min read

Capital markets

The listing is the asset

The industry calls the constraint on biotech reverse mergers a shell shortage. There is no shortage of failed biotechs, nor of cash inside them. What runs short is the moment a board agrees its company is finished.

8 min read

Cross-border BD

Devices, not just drugs

Biotech discourse fixates on drugs. The first wave of US-Taiwan wins is more likely to land in medical devices, where the regulatory clock runs in months, not years.

7 min read

Cross-border BD

Taiwan: the fastest front door to Asia

The reflex is Japan, then Korea, then China. For a US-originated asset the fastest first market is Taiwan, and the case is a schedule, not sentiment.

7 min read

If one of these decisions is on your desk, I would welcome a conversation.